Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2021

01-03-2021 | Metastasis | Endocrine Tumors

Comparison Between Familial and Sporadic Non-medullary Thyroid Carcinoma: A Retrospective Individual Risk Factor-Matched Cohort Study

Authors: Yu-Mi Lee, MD, PhD, Min Ji Jeon, MD, PhD, Won Woong Kim, MD, Ki-Wook Chung, MD, PhD, Jung Hwan Baek, MD, PhD, Young Kee Shong, MD, PhD, Tae-Yon Sung, MD, PhD, Suck Joon Hong, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2021

Login to get access

Abstract

Background

This study aimed to compare clinicopathologic features and outcomes between patients with familial non-medullary thyroid carcinoma (FNMTC) and patients with sporadic non-medullary thyroid carcinoma (SNMTC) after performing individual risk factor-matching. Additionally, the study evaluated a dynamic risk stratification (DRS) system to validate its usefulness for familial-type thyroid carcinoma.

Methods

After individual risk factor-matching, 286 patients remained in the FNMTC group, and 858 patients were assigned to the SNMTC group consisting of papillary thyroid carcinoma (PTC). The prognostic outcomes were compared between the two groups in a matched cohort.

Results

During the mean follow-up period of 142 months, recurrences were experienced by 64 patients in the sporadic group (7.5%) and 29 patients in the familial group (10.1%). In the multivariate analysis, the independent risk factors for recurrence were primary tumor size (p = 0.033), gross extrathyroidal extension (p = 0.001), and lymph node metastasis (p < 0.001). The independent risk factors did not include family history alone (p = 1.101) or the number of affected family members (p = 0.122 for 2 members and p = 0.625 for ≥ 3 members). In this matched-cohort study, the DRS system was well adjusted in the FNMTC and SNMTC groups. Moreover, the proportion of DRS categories and the recurrence rate in each DRS category were similar between the familial and sporadic groups.

Conclusions

Family history did not present a statistically significant association with a poor prognosis for PTC patients. With a family history of PTC alone, less aggressive treatment could be considered. In this matched cohort, DRS was adjusted well and could be useful in predicting prognosis, even for PTC patients with a family history of PTC.
Literature
1.
go back to reference Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017;77:140–52.CrossRef Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017;77:140–52.CrossRef
2.
go back to reference Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–48.CrossRef Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–48.CrossRef
3.
go back to reference Sturgeon C, Clark OH. Familial nonmedullary thyroid cancer. Thyroid. 2005;15:588–93.CrossRef Sturgeon C, Clark OH. Familial nonmedullary thyroid cancer. Thyroid. 2005;15:588–93.CrossRef
4.
go back to reference Nixon IJ, Suarez C, Simo R, et al. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol. 2016;42:1455–63.CrossRef Nixon IJ, Suarez C, Simo R, et al. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol. 2016;42:1455–63.CrossRef
5.
go back to reference Robinson DW, Orr TG. Carcinoma of the thyroid and other diseases of the thyroid in identical twins. AMA Arch Surg. 1955;70:923–8.CrossRef Robinson DW, Orr TG. Carcinoma of the thyroid and other diseases of the thyroid in identical twins. AMA Arch Surg. 1955;70:923–8.CrossRef
6.
go back to reference Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”–screening and overdiagnosis. N Engl J Med. 2014;371:1765–7.CrossRef Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”–screening and overdiagnosis. N Engl J Med. 2014;371:1765–7.CrossRef
7.
go back to reference Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.CrossRef Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.CrossRef
8.
go back to reference Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.CrossRef Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.CrossRef
9.
go back to reference Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128:1043–50; discussion 1050–1. Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128:1043–50; discussion 1050–1.
10.
go back to reference Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15:1075–81.CrossRef Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15:1075–81.CrossRef
11.
go back to reference Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg. 1995;130:892–7; discussion 898–9. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg. 1995;130:892–7; discussion 898–9.
12.
go back to reference Lei S, Wang D, Ge J, et al. Single-center study of familial papillary thyroid cancer in China: surgical considerations. World J Surg Oncol. 2015;13:115.CrossRef Lei S, Wang D, Ge J, et al. Single-center study of familial papillary thyroid cancer in China: surgical considerations. World J Surg Oncol. 2015;13:115.CrossRef
13.
go back to reference Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26:897–902.CrossRef Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26:897–902.CrossRef
14.
go back to reference Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H, Sippel RS. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 2012;22:3–8.CrossRef Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H, Sippel RS. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 2012;22:3–8.CrossRef
15.
go back to reference Park YJ, Ahn HY, Choi HS, Kim KW, Park DJ, Cho BY. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 2012;22:356–62.CrossRef Park YJ, Ahn HY, Choi HS, Kim KW, Park DJ, Cho BY. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 2012;22:356–62.CrossRef
16.
go back to reference Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21:43–8.CrossRef Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21:43–8.CrossRef
17.
go back to reference Ito Y, Kakudo K, Hirokawa M, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145:100–5.CrossRef Ito Y, Kakudo K, Hirokawa M, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145:100–5.CrossRef
18.
go back to reference Maxwell EL, Hall FT, Freeman JL. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope. 2004;114:2182–6.CrossRef Maxwell EL, Hall FT, Freeman JL. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope. 2004;114:2182–6.CrossRef
19.
go back to reference Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 2011;21:367–71.CrossRef Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 2011;21:367–71.CrossRef
20.
go back to reference Pinto AE, Silva GL, Henrique R, et al. Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. Eur J Endocrinol. 2014;170:321–7.CrossRef Pinto AE, Silva GL, Henrique R, et al. Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. Eur J Endocrinol. 2014;170:321–7.CrossRef
21.
go back to reference Triponez F, Wong M, Sturgeon C, et al. Does familial non-medullary thyroid cancer adversely affect survival? World J Surg. 2006;30:787–93.CrossRef Triponez F, Wong M, Sturgeon C, et al. Does familial non-medullary thyroid cancer adversely affect survival? World J Surg. 2006;30:787–93.CrossRef
22.
go back to reference Zhang Q, Yang S, Meng XY, Chen G, Pang RZ. Clinical analysis of familial nonmedullary thyroid carcinoma. World J Surg. 2016;40:570–3.CrossRef Zhang Q, Yang S, Meng XY, Chen G, Pang RZ. Clinical analysis of familial nonmedullary thyroid carcinoma. World J Surg. 2016;40:570–3.CrossRef
23.
go back to reference Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol Oxford. 2014;81(Suppl 1):1–122.CrossRef Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol Oxford. 2014;81(Suppl 1):1–122.CrossRef
24.
go back to reference Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.CrossRef Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.CrossRef
25.
go back to reference Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–21.CrossRef Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43:401–21.CrossRef
26.
go back to reference Momesso DP, Vaisman F, Yang SP, et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab. 2016;101:2692–700.CrossRef Momesso DP, Vaisman F, Yang SP, et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J Clin Endocrinol Metab. 2016;101:2692–700.CrossRef
27.
go back to reference Kwon H, Kim WG, Jeon MJ, et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine. 2016;53:174–81.CrossRef Kwon H, Kim WG, Jeon MJ, et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine. 2016;53:174–81.CrossRef
28.
go back to reference Lee YM, Cho JW, Hong SJ, Yoon JH. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. J Surg Oncol. 2018;118:636–43.CrossRef Lee YM, Cho JW, Hong SJ, Yoon JH. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. J Surg Oncol. 2018;118:636–43.CrossRef
29.
go back to reference Zanella AB, Scheffel RS, Nava CF, et al. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer. Thyroid. 2018;28:1285–92.CrossRef Zanella AB, Scheffel RS, Nava CF, et al. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer. Thyroid. 2018;28:1285–92.CrossRef
30.
go back to reference Ammar SA, Alobuia WM, Kebebew E. An update on familial nonmedullary thyroid cancer. Endocrine. 2020;68:502–7. Ammar SA, Alobuia WM, Kebebew E. An update on familial nonmedullary thyroid cancer. Endocrine. 2020;68:502–7.
31.
go back to reference Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRef Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRef
32.
go back to reference Wang F, Yu X, Shen X, et al. The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. J Clin Endocrinol Metab. 2017;102:3241–50.CrossRef Wang F, Yu X, Shen X, et al. The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. J Clin Endocrinol Metab. 2017;102:3241–50.CrossRef
33.
go back to reference Huang H, Liu S, Xu Z, Ni S, Zhang Z, Wang X. Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma. Medicine Baltimore. 2017;96:e7461.CrossRef Huang H, Liu S, Xu Z, Ni S, Zhang Z, Wang X. Long-term outcome of thyroid lobectomy for unilateral multifocal papillary carcinoma. Medicine Baltimore. 2017;96:e7461.CrossRef
34.
go back to reference Kwon H, Oh HS, Kim M, et al. Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea. J Clin Endocrinol Metab. 2017;102:1917–25.CrossRef Kwon H, Oh HS, Kim M, et al. Active surveillance for patients with papillary thyroid microcarcinoma: a single center’s experience in Korea. J Clin Endocrinol Metab. 2017;102:1917–25.CrossRef
35.
go back to reference Jeon MJ, Kim WG, Chung KW, Baek JH, Kim WB, Shong YK. Active surveillance of papillary thyroid microcarcinoma: where do we stand? Eur Thyroid J. 2019;8:298–306.CrossRef Jeon MJ, Kim WG, Chung KW, Baek JH, Kim WB, Shong YK. Active surveillance of papillary thyroid microcarcinoma: where do we stand? Eur Thyroid J. 2019;8:298–306.CrossRef
Metadata
Title
Comparison Between Familial and Sporadic Non-medullary Thyroid Carcinoma: A Retrospective Individual Risk Factor-Matched Cohort Study
Authors
Yu-Mi Lee, MD, PhD
Min Ji Jeon, MD, PhD
Won Woong Kim, MD
Ki-Wook Chung, MD, PhD
Jung Hwan Baek, MD, PhD
Young Kee Shong, MD, PhD
Tae-Yon Sung, MD, PhD
Suck Joon Hong, MD, PhD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09025-0

Other articles of this Issue 3/2021

Annals of Surgical Oncology 3/2021 Go to the issue